Tirzepatide
well-studiedA dual GIP/GLP-1 receptor agonist showing even greater weight loss results than semaglutide in clinical trials.
Overview
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It works through two complementary pathways, which may explain its superior efficacy compared to GLP-1-only agonists.
The SURMOUNT clinical trials showed average weight loss of 20-25% of body weight — significantly more than semaglutide. Sold as Mounjaro (diabetes) and Zepbound (weight management). It represents the current frontier of pharmaceutical weight management.
Benefits
- ✓Superior weight loss vs semaglutide (20-25%)
- ✓Dual mechanism of action
- ✓Improved insulin sensitivity
- ✓Significant HbA1c reduction
- ✓Cardiovascular benefits
- ✓Once-weekly dosing
Side Effects
- ⚠Nausea (common during titration)
- ⚠Diarrhea
- ⚠Decreased appetite (intended effect)
- ⚠Injection site reactions
- ⚠Potential pancreatitis risk
- ⚠Gallbladder issues
⚠ Research Disclaimer: This information is for educational purposes only and is not medical advice. Consult a qualified healthcare professional before using Tirzepatide or any peptide. See our full medical disclaimer.